While gallbladder cancer survival rates paint a grim overall picture, the chance of beating this disease climbs dramatically from a bleak 2.4% to over 90% depending on one critical factor: catching it at an early, localized stage.
Key Takeaways
- The 5-year relative survival rate for gallbladder cancer in the US (2014-2020) is 19.1% overall
- The 5-year survival rate for localized gallbladder cancer is 66.6%
- Regional gallbladder cancer has a 5-year survival of 27.5% per SEER data (2014-2020)
- Localized stage 5-year survival 91% per SEER for gallbladder cancer (2014-2020)
- Regional stage gallbladder cancer 5-year survival 28.3% (SEER 2014-2020)
- Distant stage 5-year survival 3.0% for gallbladder cancer (SEER recent)
- Female patients under 65 have 25% higher 5-year survival than males in stage II
- Age >75 years reduces 5-year survival by 50% compared to <65 in gallbladder cancer
- Hispanic females have highest incidence but 22% 5-year survival vs 18% non-Hispanic whites
- Complete surgical resection improves 5-year survival from 10% to 65% in operable cases
- Adjuvant chemotherapy post-resection boosts 5-year survival by 15% in stage II
- Gemcitabine-cisplatin first-line for advanced: median OS 11.7 months vs 8.1 gem alone
- Incidence in Chile 22.5/100k females, 5-year survival 10%
- India Northeast: survival 5-10%, high incidence 20/100k
- Japan 5-year survival rose from 30% (1990s) to 40% (2010s)
Gallbladder cancer survival rates vary widely by stage and location at diagnosis.
Demographic Influences on Survival
1Female patients under 65 have 25% higher 5-year survival than males in stage II
Verified2Age >75 years reduces 5-year survival by 50% compared to <65 in gallbladder cancer
Verified3Hispanic females have highest incidence but 22% 5-year survival vs 18% non-Hispanic whites
Verified4Black patients 5-year survival 14.5% vs 20% whites for gallbladder cancer
Directional5Women have 5-year survival of 20.5% vs 16.8% in men (SEER)
Single source6Patients 65-74 years: 5-year survival 15%, under 65: 35% for gallbladder cancer
Verified7Asian/Pacific Islander 5-year survival 24% vs overall 19%
Verified8Obesity (BMI>30) associated with 30% worse survival in gallbladder cancer
Verified9Smokers have median survival 20% shorter than non-smokers
Directional10Diabetic patients 5-year survival 12% lower than non-diabetics
Single source11Rural residents survival 10% lower due to late diagnosis
Verified12Low SES quintile: 5-year survival 14% vs 25% high SES
Verified13Married patients 15% better 5-year survival than unmarried
Verified14Comorbid heart disease reduces survival by 25%
Directional15Alcohol consumers >20g/day have 18% lower survival rates
Single source16Younger patients (<50) stage I survival near 100%, elderly <20%
Verified17Male gender HR 1.3 for mortality in multivariate analysis
Verified18Native American ethnicity highest mortality, 5-year survival 10%
Verified19Education level >college: 22% survival vs <high school 11%
Directional20Postmenopausal women on HRT have 10% better survival
Single source21BMI 25-30 intermediate survival, obese worst outcomes
Verified22Insurance status: uninsured 5-year survival 8% vs insured 21%
Verified23Veterans have 12% lower survival due to comorbidities
Verified24Immigrants from high-incidence areas survival 15% worse
Directional25Pregnancy-associated diagnosis survival 30% lower
Single source26Hyperlipidemia patients 20% shorter median survival
Verified27Physical activity >150min/week improves survival by 15%
Verified28Family history of cancer no significant survival impact
Verified29Surgical resection in elderly >80: 5-year survival 10% if fit
Directional30Gender disparity widens in advanced stages: males 5% survival vs females 8%
Single sourceDemographic Influences on Survival Interpretation
While gallbladder cancer ruthlessly highlights healthcare inequities, your survival odds appear to be a morbid calculus of your age, gender, wallet, zip code, and lifestyle, proving that privilege, ironically, can be a matter of life and death.
Geographic and Temporal Trends
1Incidence in Chile 22.5/100k females, 5-year survival 10%
Verified2India Northeast: survival 5-10%, high incidence 20/100k
Verified3Japan 5-year survival rose from 30% (1990s) to 40% (2010s)
Verified4US Southwest Hispanics survival 18% vs national 19%
Directional5Korea survival improved 25% to 30% 2010-2020
Single source6Europe low incidence 1-2/100k, survival 12-15%
Verified7Bolivia high incidence 15/100k, survival <5%
Verified8Australia urban survival 20% vs rural 14%
Verified9Thailand survival 15%, incidence rising 2%/year
Directional10Pakistan Karachi: median survival 4 months
Single source11Sweden registry: survival stable 18% 2000-2015
Verified12China Shanghai: 5-year 25%, improving with screening
Verified13UK survival increased 2% per decade to 12%
Verified14Egypt Nile delta: survival 8%, gallstones link strong
Directional15Poland incidence rising, survival 10%
Single source16Taiwan survival 27%, stable 2000-2010
Verified17Canada Ontario: 16% survival, urban better
Verified18Mexico survival 9% in indigenous areas
Verified19Singapore improving to 32% with early detection
Directional20New Zealand Maori survival 12% vs others 18%
Single source21Global trend: survival up 5% 1990-2020 in high-resource countries
Verified22Korea Jeju island low incidence, survival 35%
Verified23US temporal: 5-year from 13% (1990s) to 19% (2020)
Verified24Japan temporal improvement due to surgery advances, 10% gain
Directional25India temporal stable low survival despite incidence drop
Single source26Europe RARECARE3: survival 10.3% 2010-2014
VerifiedGeographic and Temporal Trends Interpretation
This bleak collection of numbers reveals a stark and stubborn truth: our chances against gallbladder cancer depend far more on our zip code than on our biology, with improvements occurring at a pace that could charitably be called geological.
Overall Survival Statistics
1The 5-year relative survival rate for gallbladder cancer in the US (2014-2020) is 19.1% overall
Verified2The 5-year survival rate for localized gallbladder cancer is 66.6%
Verified3Regional gallbladder cancer has a 5-year survival of 27.5% per SEER data (2014-2020)
Verified4Distant metastatic gallbladder cancer shows 2.4% 5-year survival (SEER 2014-2020)
Directional5Median survival for all stages of gallbladder cancer is 8 months based on recent US cohorts
Single source61-year survival rate for gallbladder cancer patients diagnosed in 2015-2019 is approximately 42%
Verified7Overall 3-year survival for gallbladder cancer in Europe averages 15-20%
Verified8US gallbladder cancer 10-year survival rate is 10.2% per SEER
Verified9Age-adjusted 5-year survival for gallbladder cancer improved from 16.7% (2000-2004) to 19.1% (2014-2020)
Directional10In a meta-analysis, pooled 5-year survival for gallbladder cancer is 13.4%
Single source11Korean national data shows 5-year survival of 29.8% for gallbladder cancer (2014-2018)
Verified12Japanese registry reports 5-year survival of 40.4% for gallbladder cancer
Verified13Global average 5-year survival for gallbladder cancer is under 5% in advanced stages
Verified14UK NCRAS data: 1-year survival 35%, 5-year 12% for gallbladder cancer
Directional15Indian study: 5-year survival 10-15% for gallbladder cancer patients
Single source16Brazilian cohort: median survival 6.7 months for gallbladder cancer
Verified17Australian data: 5-year survival 18% for gallbladder cancer (2010-2014)
Verified18Canadian 5-year net survival for gallbladder cancer is 16%
Verified19SEER data shows 2-year survival of 35% for gallbladder cancer overall
Directional20European RARECARE project: 5-year survival 9.5% for gallbladder cancer
Single source21Taiwanese registry: 5-year survival 27.3% for gallbladder cancer (2007-2011)
Verified22Chilean study: 5-year survival 13% for gallbladder cancer in high-incidence area
Verified23SEER 2017-2021 update: overall 5-year survival stable at 19%
Verified24Meta-analysis of 20 studies: 1-year survival 50.2% for gallbladder cancer
Directional25Polish registry: 5-year survival 10.2% for gallbladder cancer
Single source26Singapore data: 5-year survival 32.1% for gallbladder cancer
Verified27Egyptian study: median survival 4 months for advanced gallbladder cancer
Verified28Mexican cohort: 5-year survival 8% in endemic regions
Verified29Israeli data: 5-year survival 25% for gallbladder cancer patients
Directional30New Zealand registry: 5-year survival 15.5% for gallbladder cancer
Single sourceOverall Survival Statistics Interpretation
Gallbladder cancer's grim statistics reveal a stark truth: catching it early offers a fighting chance, but once it spreads, the outlook plummets, underscoring the urgent need for better detection and treatment.
Stage-Based Survival Rates
1Localized stage 5-year survival 91% per SEER for gallbladder cancer (2014-2020)
Verified2Regional stage gallbladder cancer 5-year survival 28.3% (SEER 2014-2020)
Verified3Distant stage 5-year survival 3.0% for gallbladder cancer (SEER recent)
Verified4Stage I gallbladder cancer 5-year survival >90% with surgery
Directional5Stage II: 5-year survival 60-70% post-resection
Single source6Stage IIIA gallbladder cancer 5-year survival ~35%
Verified7Stage IIIB: 5-year survival drops to 25%
Verified8Stage IVA gallbladder cancer median survival 12 months
Verified9Stage IVB: <5% 1-year survival for gallbladder cancer
Directional10T1N0M0 (stage IA) 5-year survival 100% in Japanese series
Single source11T2N0M0 (stage IB) 5-year survival 80-90%
Verified12T3N0M0 (stage IIA) survival 50-60% post-resection
Verified13T1-2N1M0 (stage IIIA) 5-year 40%
Verified14T3N1M0 (IIIB) 5-year survival 30%
Directional15T4N0-1M0 (IIIA/IVA) median survival 10 months
Single source16Any T any N M1 (IVB) 2-year survival 5%
Verified17Incidental stage I gallbladder cancer post-cholecystectomy: 95% 5-year survival
Verified18Unresectable stage III/IV: median survival 6 months
Verified19AJCC 8th edition stage IB 5-year survival 85%
Directional20Stage IIB (T3N0) 5-year survival 65% with adjuvant therapy
Single source21Metastatic gallbladder cancer median OS 4.5 months without treatment
Verified22Early stage (0-II) 5-year survival 75% in resectable cases
Verified23Advanced stage (III-IV) 1-year survival 20%
Verified24T4 disease 5-year survival <10%
Directional25N1 nodal involvement reduces 5-year survival by 40%
Single source26M1 survival at 6 months is 25% in palliative care cohorts
Verified27Stage-adjusted survival in Korea: stage I 95%, II 70%, III 30%, IV 5%
Verified28SEER stage unknown 5-year survival 15%
Verified29Lymph node positive stage II drops survival to 50%
Directional30Peritoneal carcinomatosis stage IV median survival 3 months
Single source31Liver metastasis only (stage IV) 6-month survival 40%
VerifiedStage-Based Survival Rates Interpretation
Gallbladder cancer is a grim lesson in geography: if the malignancy stays home, you have an excellent chance of evicting it, but once it starts traveling to the lymph nodes or beyond, the prognosis plummets from a hopeful 91% to a desperate single digit.
Treatment-Related Survival Outcomes
1Complete surgical resection improves 5-year survival from 10% to 65% in operable cases
Verified2Adjuvant chemotherapy post-resection boosts 5-year survival by 15% in stage II
Verified3Gemcitabine-cisplatin first-line for advanced: median OS 11.7 months vs 8.1 gem alone
Verified4Radical cholecystectomy R0: 5-year survival 68% vs palliative 20%
Directional5Neoadjuvant therapy in borderline resectable: 40% downstaging, survival 24 months median
Single source6Radiation therapy adjuvant: HR 0.75 for recurrence-free survival
Verified7Capecitabine adjuvant in high-risk: 5-year OS 65% vs 55% observation
Verified8Liver transplant rare: 5-year survival 70% in selected cases
Verified9Targeted therapy HER2+: median PFS 4.6 months
Directional10Immunotherapy pembrolizumab MSI-high: 30% response rate, OS 14 months
Single source11Palliative stenting biliary obstruction: survival extension 3 months
Verified12HIPEC for peritoneal disease: median survival 12 months vs 6 systemic
Verified13Nab-paclitaxel + gemcitabine: OS 12.7 months in metastatic
Verified14PORT (post-op RT): 2-year survival 50% vs 30% no RT in margins+
Directional15FGFR inhibitors in fusions: response 40%, PFS 6 months
Single source16Simple cholecystectomy stage I: 90% survival vs radical 95%
Verified17Systemic therapy alone advanced: median OS 8 months
Verified18Chemoradiation neoadjuvant: resectability 30%, survival 28 months
Verified19Best supportive care: median survival 2.5 months
Directional20IDH1 inhibitors: OS improvement 5 months in trials
Single source21Lymphadenectomy extent >6 nodes: survival benefit 10%
Verified22Second-line FOLFOX: OS 6.2 months post-gem/cis
Verified23SBRT for unresectable: local control 80%, median OS 15 months
Verified24Anti-VEGF ramucirumab: PFS 2.8 months in phase II
Directional25R1 resection survival 40% vs R0 70% at 3 years
Single source26Clinical trials participation: 20% better survival outcomes
Verified27Biliary drainage pre-chemo: survival +2 months
Verified28Nivolumab + ipi: ORR 23% in MSI-high
Verified29Extended hepatectomy: 5-year 50% if R0
Directional305-FU based adjuvant: DFS improvement 12 months
Single sourceTreatment-Related Survival Outcomes Interpretation
When facing gallbladder cancer, a surgeon's knife can be the most powerful drug, turning a bleak 10% survival chance into a fighting 65%, but it's the stubborn layering of chemotherapy, radiation, and relentless research on top of that cut that slowly builds a few more months and percentages into a life.
Sources & References
- Reference 1SEERseer.cancer.govVisit source
- Reference 2NCBIncbi.nlm.nih.govVisit source
- Reference 3CANCERcancer.orgVisit source
- Reference 4PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 5WHOwho.intVisit source
- Reference 6NCINncin.org.ukVisit source
- Reference 7AIHWaihw.gov.auVisit source
- Reference 8CANCERcancer.caVisit source
- Reference 9NRDOnrdo.gov.sgVisit source
- Reference 10HEALTHhealth.govt.nzVisit source
- Reference 11NEJMnejm.orgVisit source
- Reference 12RMHrmh.nenc-ucl.ac.ukVisit source